80352-59-6Relevant academic research and scientific papers
Propargylic C[sbnd]H activation using a Cu(II) 2-quinoxalinol salen catalyst and tert-butyl hydroperoxide
Black, Clayton C.,Gorden, Anne E.V.
supporting information, p. 803 - 806 (2018/02/06)
The oxidation of alkynes to α,β-acetylenic carbonyls was achieved using only 1 mol% of a Cu(II) 2-quinoxalinol salen catalyst with tert-butyl hydroperoxide. These reactions proceed under mild conditions (70 °C) with excellent selectivity, producing yields up to 78%, and were used on a variety of alkyne substrates to produce the desired corresponding α,β-acetylenic ketones. In addition, these reactions can be run under aqueous conditions using a sulfonated version of the 2-quinoxalinol salen with good yields, reducing the need for volatile organic solvents.
Ferrocenyl, Alkyl, and Aryl-Pyrido[2,3-d]Pyrimidines as Vasorelaxant of Smooth Muscle of Rat Aorta via cAMP Conservation Through Phosphodiesterase Inhibition
Arellano, Ivonne,Rodríguez-Ramos, Fernando,González-Andrade, Martín,Navarrete, Andrés,Sharma, Manju,Rosas, Noé,Sharma, Pankaj
, p. 1147 - 1154 (2016/07/29)
New pyrido[2,3-d]pyrimidines 11, 12, 13, and 21 have been synthesized. The vasorelaxant effect on smooth muscle isolated from rat aorta, via PDEs inhibition, of these compounds along with other pyrido[2,3-d]pyrimidines 14, 15, 16, 17, 18, 19, 20 reported earlier by our group, has also been determined. These pyrido[2,3-d]pyrimidines 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 were synthesized by the reaction of ferrocenyl-ethynyl ketones (1, 2, 3, 4) or α-alkynyl ketones (5, 6, 7, 8, 9, 10) with 6-amino-1,3-dimethyluracil using [Ni(CN)4]?4as an active catalytic species, formed in situ in a Ni(CN)2/NaOH/H2O/CO/KCN aqueous system. Evaluation of the vasorelaxant effect of compounds 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 demonstrated that all compounds relax the tissue in a concentration-dependent manner. The structural changes do not alter the effectiveness; however, there are differences related to potency expressed as EC50. Compounds 12 (7-ferrocenyl-1,3-dimethyl-5-(m-tolyl)-pyrido[2,3-d]pyrimidine) and 13 (7-ferrocenyl-1,3-dipropyl-5-(4-metoxyphenyl)-pyrido[2,3-d]pyrimidine) were the most potent compounds, even more than rolipram, reference drug; the EC50was 0.41 ± 0.02 μM and 0.81 ± 0.11 μM for 12 and 13, correspondingly. The EC50of compounds 15 (7-ferrocenyl-1,3-dimethyl-5-phenyl-pyrido[2,3-d]pyrimidine), 14 (7-ferrocenyl-5-(3,5-dimethoxyphenyl)-1,3-dimethylpyrido[2,3-d]pyrimidine), and 19 (5-n-butyl-7-ethyl-1,3-dimethylpyrido[2,3-d]pyrimidine) was similar to EC50of rolipram. Compounds 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 significantly induce concentration-dependent vasorelaxation in endothelium-intact aortic rings. In addition, the relaxation responses to each compound in either endothelium-intact or endothelium denuded aortic rings were comparable, suggesting that removal of the functional endothelium has no significant influence on its intrinsic vasorelaxant activity. In vitro capability of conserving cyclic-AMP or cyclic-GMP (adenosine and guanosine 3′, 5′-cyclic monophosphate) via PDE inhibition for compounds 12, 13, 14, 15 and 19 was evaluated. Compounds 15 and 19 show the highest percent inhibition effect (94.83% and 83.98%, respectively) for the decomposition of c-AMP. Docking studies showed that the compound 15 was selective for the inhibition of PDE-4.
Discovery of pyrazolo[1,5-a]pyridines as p110α-selective PI3 kinase inhibitors
Kendall, Jackie D.,O'Connor, Patrick D.,Marshall, Andrew J.,Frédérick, Rapha?l,Marshall, Elaine S.,Lill, Claire L.,Lee, Woo-Jeong,Kolekar, Sharada,Chao, Mindy,Malik, Alisha,Yu, Shuqiao,Chaussade, Claire,Buchanan, Christina,Rewcastle, Gordon W.,Baguley, Bruce C.,Flanagan, Jack U.,Jamieson, Stephen M.F.,Denny, William A.,Shepherd, Peter R.
experimental part, p. 69 - 85 (2012/03/08)
We have made a novel series of pyrazolo[1,5-a]pyridines as PI3 kinase inhibitors, and demonstrated their selectivity for the p110α isoform over the other Class Ia PI3 kinases. We investigated the SAR around the pyrazolo[1,5-a]pyridine ring system, and found compound 5x to be a particularly potent example (p110α IC50 0.9 nM). This compound inhibits cell proliferation and phosphorylation of Akt/PKB, a downstream marker of PI3 kinase activity, and showed in vivo activity in an HCT-116 human xenograft model.
Ni(0) catalyzed one step synthesis of benzo[b][1,8] naphthyridin-5-ones from silyl-α-ketoalkynes in water
Suárez-Ortiz, Gloria Alejandra,Sharma, Pankaj,Amézquita-Valencia, Manuel,Arellano, Ivonne,Cabrera,Rosas, Noé
scheme or table, p. 1641 - 1643 (2011/04/25)
One-step synthesis of new benzo[b][1,8]naphthyridin-5-ones using a Ni(0) catalytic system in aqueous medium with mild conditions of pressure and temperature is described. It is very interesting to note that Ni(0) catalyst increases the rate of condensation of several α-ketoalkynes with 2-amino-4(1H)-quinolinone obtaining benzo[b][1,8]naphthyridin-5-ones in very high yield. In the absence of catalyst this condensation reaction takes 24 h with a product yield of 10%.
PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE IN CANCER THERAPY
-
Page/Page column 26-27, (2010/07/09)
The invention relates to pyrazolo[1,5-a]pyridine and/or -imidazo[1,2-a]pyridine derivatives, to their preparation, to their use as agents or drugs for cancer prevention or therapy for treating cancer, either alone or in combination with radiation and/or anticancer drugs.
Metal cation-exchanged montmorillonite (Mn+-mont)-catalyzed friedel-crafts acylation of 1-methyl-1-cyclohexene and 1-trimethylsilyl-1- alkynes
Nishimura, Takahiro,Ohtaka, Seiji,Hashimoto, Keiji,Yamauchi, Takayoshi,Hasegawa, Takuji,Imanaka, Kaori,Tateiwa, Jun-Ichi,Takeuchi, Hiroshi,Uemura, Sakae
, p. 1765 - 1766 (2007/10/03)
The acylation of 1-methyl-1-cyclohexene and 1-trimethylsilyl-1-alkynes with acyl chlorides has been investigated in the presence of a variety of metal cation-exchanged montmorillonites (abbreviated as Mn+-monts), where the catalysts are recycla
Asymmetric reduction of ethynyl ketones and ethynylketoesters by secondary alcohol dehydrogenase from Thermoanaerobacter ethanolicus
Heiss, Christian,Phillips, Robert S.
, p. 2821 - 2825 (2007/10/03)
Secondary alcohol dehydrogenase (SADH) from Thermoanaerobacter ethanolicus, an NADP-dependent, thermostable oxidoreductase, reduces ethynyl ketones and ethynylketoesters enantioselectively to the corresponding propargyl (propargyl = prop-2-ynyl) alcohols. Ethynyl ketones, in general, are reduced with moderate enantioselectivity (with the exception of 4-methylpent-l-yn-3-one, which gives the (S)-alcohol with >98% ee). Although ethynyl ketones bearing a small (up to n-propyl) alkyl substituent are reduced to (S)-alcohols, larger ethynyl ketones give (R)-alcohols. In contrast, ethynylketoesters are converted to (R)-ethynylhydroxyesters of excellent optical purity. Unexpectedly, isopropyl ethynylketoesters give higher chemical yields and higher enantioselectivities of ethynylhydroxyesters than methyl or ethyl ethynylketoesters. The optically pure ethynylhydroxyesters may serve as useful chiral building blocks for asymmetric synthesis.
A Pseudomonas sp. Alcohol Dehydrogenase with Broad Substrate Specificity and Unusual Stereospecificity for Organic Synthesis
Bradshaw, Curt W.,Fu, Hong,Shen, Gwo-Jenn,Wong, Chi-Huey
, p. 1526 - 1532 (2007/10/02)
A new alcohol dehydrogenase from Pseudomonas sp. strian PED has been isolated and characterized.The enzyme exhibits a broad substrate specificity, accepting aromatic, cyclic, and aliphatic compounds as substrates.The Km values were determined as 525 μM for NAD and 75 μM for 2-propanol with a specific activity of 36 U/mg.The kinetic mechanism is ordered bi-bi with the cofactor binding first and releasing last.The enzyme transfers the pro-R hydride of NADH to the si face of carbonyl compounds to yield (R) alcohols.Synthetic-scale reductions of a number of representative compounds were carried out in high enentiomeric excess with in situ regeneration of NADH using 2-propanol as the hydride source and the same enzyme as catalyst.
